ClinicalTrials.gg

Ovarian Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,390 studies for Ovarian Neoplasms across more than 10 countries. 791 are recruiting or about to start. 1,883 of them are mainly about Ovarian Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its 5 narrower conditions too, such as Carcinoma, Ovarian Epithelial: 3,850 studies, 866 open.

ClinicalTrials.gov finds 5,351 studies for Ovarian Neoplasms. How that becomes 3,385 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Ovarian Neoplasms, and those it files under no condition that list Ovarian Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 5,351Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −445Filed under a narrower condition, counted on its own pageCarcinoma, Ovarian Epithelial 354 · Hereditary Breast and Ovarian Cancer Syndrome 45 · Carcinoma, Endometrioid 18 · Ovarian Germ Cell Cancer 6 · Brenner Tumor 5
  3. −88List Ovarian Neoplasms as a condition, but the registry did not file them under itMost often written as “Stage III Ovarian Cancer AJCC v6 and v7” (9), “Stage IV Ovarian Cancer AJCC v6 and v7” (9), and “High Grade Serous Ovarian Cancer” (8). The registry filed them under other conditions only, most often Fallopian Tube Neoplasms (28) and Triple Negative Breast Neoplasms (13).
  4. −1,433Match it another way93 name it in the title, 13 in a keyword, and 1,327 by a synonym or other text the search reads.
  5. 3,385The count on this page114 of them list Ovarian Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
1,495
Recruiting
602
Terminated
393
Status unknown
324
Active, not recruiting
253
Not yet recruiting
172

Phase

Phase 2
1,245
Phase 1
1,052
Phase 3
274
Early Phase 1
51
Phase 4
33

Where

United States
1,780
China
394
United Kingdom
293
France
291
Canada
273
Spain
268

Who develops what

Add Ovarian Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 135 programs from 98 companies, 66 with this as their studies’ main aim; 22 with a live phase 3 study; 33 primary completions in the next 12 months. Compare Beijing Biotech, Hansoh Pharmaceutical Group and Merck here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PaclitaxelRecent, repeated
Evidence
  • NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Oct 2026
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2026
  • NCT07714668 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “paclitaxel, carboplatin, bevacizumab” · registered Jul 2026
  • NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Paclitaxel” · registered May 2026
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed2129 studies
BevacizumabRecent, repeated
Evidence
  • NCT07859215 · Genmab · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
  • NCT07816666 · AstraZeneca · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
  • NCT07797283 · Incyte Corporation · Phase 3 · live · background · “Bevacizumab” · registered Aug 2026
  • NCT07776691 · Merck & Co., Inc · Phase 3 · live · background · “Bevacizumab” · registered Aug 2026
  • NCT07779538 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “bevacizumab” · registered Aug 2026
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others1328 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Carboplatin” · registered Jul 2026
  • NCT07714668 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “paclitaxel, carboplatin, bevacizumab” · registered Jul 2026
  • NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Carboplatin” · registered Jun 2026
  • NCT07564141 · Genmab · Phase 3 · live · comparator · “Carboplatin” · registered Apr 2026
  • NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Carboplatin” · registered Oct 2025
Eli Lilly and Company16% of its industry studies1216 studies
liposomal doxorubicinRecent, repeated
Evidence
  • NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Liposomal Doxorubicin” · registered Oct 2026
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Jul 2026
  • NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Jun 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered May 2026
  • NCT07564141 · Genmab · Phase 3 · live · comparator · “PLD” · registered Apr 2026
Johnson & Johnson21% of its industry studiesEU: Baxter Healthcare Corporation (EMA 1996) + 2 others1217 studies
GemcitabineRecent, repeated
Evidence
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jul 2026
  • NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Gemcitabine” · registered Jun 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered May 2026
  • NCT07564141 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2026
  • NCT07286266 · GlaxoSmithKline · Phase 3 · live · comparator · “Gemcitabine” · registered Dec 2025
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed812 studies
TopotecanRecent, repeated
Evidence
  • NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Oct 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Topotecan” · registered May 2026
  • NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Topotecan” · registered Oct 2025
  • NCT06855069 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Topotecan” · registered Feb 2025
  • NCT06828354 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Topotecan Hydrochloride for Injection” · registered Feb 2025
GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized810 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07286266 · GlaxoSmithKline · Phase 3 · live · comparator · “Pembrolizumab” · registered Dec 2025
  • NCT05797168 · AstraZeneca · Phase 2 · live · background · “Pembrolizumab” · registered Feb 2023
  • NCT05579366 · Genmab · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2022
  • NCT04561362 · BicycleTx Limited · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2020
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)44 studies
FulvestrantRecent, repeated
Evidence
  • NCT07109726 · Terremoto Biosciences Inc. · Phase 2 · live · background · “Fulvestrant injection” · registered Jul 2025
  • NCT06993844 · Ensem Therapeutics · Phase 2 · live · background · “ETX-636 dose escalation in combination with fulvestrant” · registered May 2025
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Fulvestrant” · registered Mar 2023
  • NCT05735080 · Incyclix Bio · Phase 2 · live · background · “Fulvestrant” · registered Feb 2023
  • NCT03197584 · ImmunityBio, Inc. · Phase 2 · background · “Fulvestrant” · registered Jun 2017
AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized44 studies
niraparibRecent, repeated
Evidence
  • NCT06915025 · Imunon · Phase 3 · live · background · “Niraparib” · registered Apr 2025
  • NCT06433219 · Merck KGaA, Darmstadt, Germany · Phase 2 · background · “Niraparib” · registered May 2024
  • NCT05335993 · CanariaBio Inc. · Phase 2 · live · background · “Niraparib” · registered Feb 2022
  • NCT05198804 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 2 · background · “Niraparib” · registered Dec 2021
GlaxoSmithKline53% of its industry studiesUS: GlaxoSmithKline (FDA 2023)EU: GlaxoSmithKline (EMA 2017)44 studies
DoxorubicinRecent, repeated
Evidence
  • NCT06855069 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Doxorubicin” · registered Feb 2025
  • NCT06751485 · Alphamab Oncology · Phase 3 · live · comparator · “Doxorubicin” · registered Dec 2024
  • NCT06394492 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Doxorubicin” · registered Apr 2024
  • NCT03804866 · AGC Biologics S.p.A. · Phase 2 · background · “Doxorubicin” · registered Oct 2018
  • NCT01358071 · AGC Biologics S.p.A. · Phase 2 · background · “Doxorubicin” · registered May 2011
Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed33 studies
olaparibRecent, repeated
Evidence
  • NCT06915025 · Imunon · Phase 3 · live · background · “Olaparib” · registered Apr 2025
  • NCT06686030 · Akeso · Phase 2 · live · background · “Olaparib” · registered Nov 2024
  • NCT06065059 · Tango Therapeutics, Inc. · Phase 2 · background · “Olaparib” · registered Sep 2023
  • NCT04669002 · Ellipses Pharma · Phase 2 · background · “Olaparib tablets” · registered Dec 2020
AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014)33 studies
LetrozoleRecent, repeated
Evidence
  • NCT06072781 · Verastem, Inc. · Phase 3 · live · comparator · “Letrozole” · registered Oct 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Letrozole” · registered Mar 2023
  • NCT04931342 · Hoffmann-La Roche · Phase 2 · live · background · “Letrozole” · registered Jun 2021
Novartis52% of its industry studiesUS: off-patent, 6 generics marketed22 studies
palbociclibRecent, repeated
Evidence
  • NCT06188520 · AstraZeneca · Phase 2 · live · background · “Palbociclib” · registered Dec 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Palbociclib” · registered Mar 2023
  • NCT04931342 · Hoffmann-La Roche · Phase 2 · live · background · “Palbociclib” · registered Jun 2021
Pfizer81% of its industry studiesUS: Pfizer (FDA 2015)EU: off-patent, 1 generic authorized22 studies
abemaciclibRecent, repeated
Evidence
  • NCT06188520 · AstraZeneca · Phase 2 · live · background · “Abemaciclib” · registered Dec 2023
  • NCT05735080 · Incyclix Bio · Phase 2 · live · background · “Abemaciclib” · registered Feb 2023
  • NCT04931342 · Hoffmann-La Roche · Phase 2 · live · background · “Abemaciclib” · registered Jun 2021
Eli Lilly and Company98% of its industry studiesUS: Eli Lilly and Company (FDA 2017)EU: Eli Lilly and Company (EMA 2018)22 studies
TemozolomideRecent, repeated
Evidence
  • NCT07811297 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Temozolomide (TMZ)” · registered Aug 2026
  • NCT05417594 · AstraZeneca · Phase 2 · live · background · “Temozolomide (TMZ)” · registered May 2022
  • NCT04851834 · Xennials Therapeutics Australia Pty Ltd · Phase 2 · background · “Temozolomide” · registered Apr 2021
  • NCT02836028 · Pfizer · Phase 2 · background · “Temozolomide” · registered Jul 2016
  • NCT01618136 · Eisai Co., Ltd. · Phase 2 · comparator · “E7449 plus TMZ” · registered May 2012
Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07589543 · Beijing Biotech · Phase 2 · live · background · “Cyclophosphamide” · registered May 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
  • NCT04389229 · immetacyte ltd · Phase 2 · background · “cyclophosphamide” · registered Jan 2020
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
  • NCT03197584 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Jun 2017
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07589543 · Beijing Biotech · Phase 2 · live · background · “Fludarabine” · registered May 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
  • NCT04389229 · immetacyte ltd · Phase 2 · background · “fludarabine” · registered Jan 2020
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
Beijing Biotech18% of its industry studies22 studies
AnastrozoleRecent, repeated
Evidence
  • NCT06072781 · Verastem, Inc. · Phase 3 · live · comparator · “Anastrozole” · registered Oct 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Anastrozole” · registered Mar 2023
AstraZeneca66% of its industry studiesUS: off-patent, 6 generics marketed22 studies
ribociclibRecent, repeated
Evidence
  • NCT06188520 · AstraZeneca · Phase 2 · live · background · “Ribociclib” · registered Dec 2023
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Ribociclib” · registered Mar 2023
Novartis87% of its industry studiesUS: Novartis (FDA 2017)EU: Novartis (EMA 2017)22 studies

37 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
anbenitamab repodatecan☆ Track1 live phase-3 study: NCT06751485Alphamab Oncology
mocertatug rezetecan☆ Track2 live phase-3 studies: NCT07821606, NCT06855069Hansoh Pharmaceutical Group Company Limited
mirvetuximab soravtansineApproved: US 2022 · EU 2024☆ Track1 live phase-3 study: NCT05445778AbbVie
trastuzumab rezetecan☆ Track1 live phase-3 study: NCT06828354Jiangsu HengRui Medicine Co., Ltd.
rinatabart sesutecan☆ Track5 live phase-3 studies: NCT07225270, NCT07564141, NCT06619236Genmab

The 5 in phase 3 with the nearest primary completion, of 135 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (33)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.mirvetuximab soravtansine · AbbVie · Phase 2 named, not the main aimNCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer — primary endpoint: Overall Response Rate (ORR) · 125 enrolled
  • Dec 2026 est.trastuzumab rezetecan · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimstudied with Paclitaxelstudied with Bevacizumabstudied with CarboplatinNCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer — primary endpoint: Dose limited toxicity (DLT) · 150 enrolled
  • 1 Dec 2026 est.azenosertib · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 2 main aimNCT05128825 A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer — primary endpoint: Objective Response Rate (ORR) defined by RECIST v1.1 [Part 2] · 310 enrolled

30 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Ovarian Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here PARP inhibitors 42 open · Immune checkpoint inhibitors 25 open · Angiogenesis inhibitors 20 open · Tyrosine kinase inhibitors (TKIs) 18 open · Antimitotic agents 17 open

Coming up

307studies finish main data collection within a year18 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger. 39 (6%) take children under 18. 358 (59%) are for women only and 0 (0%) for men only; 46 (8%) take healthy volunteers.

Recruiting studies that take each age, of 602
AgeWomenMen
1031 (5%)14 (2%)
18546 (91%)230 (38%)
30582 (97%)239 (40%)
40589 (98%)240 (40%)
50593 (99%)240 (40%)
65589 (98%)240 (40%)
75556 (92%)230 (38%)
85476 (79%)209 (35%)

Across all 3,390 studies, recruiting or not: 13% stop at 75 or younger and 3% at 65; 8% take children; 66% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Ovarian Neoplasms studies take

Of 380 phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 50 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 150 mo32–76 · 380 studies47 mo29–65 · 210 studies53 mo36–82 · 170 studies
Phase 1/265 mo44–88 · 173 studies61 mo44–88 · 116 studies66 mo45–110 · 57 studies
Phase 247 mo33–72 · 344 studies37 mo23–51 · 116 studies54 mo40–80 · 228 studies
Phase 359 mo37–89 · 125 studies45 mo34–72 · 73 studies81 mo48–115 · 52 studies
Interventional, no phase46 mo23–76 · 295 studies—47 mo24–76 · 284 studies
Observational61 mo35–185 · 268 studies53 mo35–71 · 52 studies71 mo35–206 · 216 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Newly registered22

Show 17 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,390. Browse all 3,390 → or search them.